Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26136590 | 0.98 | TRPV1 (0.41) | KIF11TRPV1SSTR4SSTR1ALDH1A1 | |
| SCHEMBL5709212 | 0.85 | TRPV1 (0.43) | TRPV1SSTR4SSTR1ALDH1A1MAPT | |
| SCHEMBL4947195 | 0.83 | SSTR4 (0.44) | TRPV1SSTR4SSTR1P2RY1SLC22A12 | |
| SCHEMBL29100772 | 0.83 | P2RY1 (0.44) | P2RY1 | |
| SCHEMBL4527979 | 0.82 | SSTR4 (0.46) | TRPV1SSTR4SSTR1 | |
| SCHEMBL5709016 | 0.81 | SLC22A12 (0.47) | SSTR4SSTR1P2RY1SLC22A12NFE2L2 | |
| SCHEMBL4527982 | 0.78 | SSTR4 (0.44) | TRPV1SSTR4SSTR1 | |
| SCHEMBL17558277 | 0.78 | CTNNB1 (0.45) | SSTR4SSTR1CTNNB1WNT3A | |
| SCHEMBL30783201 | 0.78 | CTNNB1 (0.45) | SSTR4SSTR1CTNNB1WNT3A | |
| SCHEMBL29142191 | 0.78 | RAB9A (0.44) | KIF11ALDH1A1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023179771-A1 | CRYSTALLINE FORMS AND SALTS OF A PI3K INHIBITOR AND METHODS OF MAKING AND METHODS OF USE THEREOF | TOTUS MEDICINES INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| EP-1957485-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | KIF11 2001/4885TRPV1 2264/4885SSTR4 398/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | KIF11 1975/4885TRPV1 2154/4885SSTR4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.